TNM: Therapeutically Not Mandatory

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1111-1116

  Epstein, Richard J ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adjuvant therapies; Cancer staging; Predictive factors; Prognostic factors; Target specific drugs

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS;

ALGORITHMS; DECISION MAKING; HUMANS; LYMPHATIC METASTASIS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; NEOPLASMS; PATIENT SELECTION; PROGNOSIS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 64349121567     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.02.020     Document Type: Article

References (28)

1. Veronesi U., Viale G., Rotmensz N., and Goldhirsch A. Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. Breast 15 1 (2006) 3-8
2. Sobin L.H. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol 21 1 (2003) 3-7
3. Balch C.M., Buzaid A.C., Soong S.J., et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 21 1 (2003) 43-52
4. Guth U., Jane Huang D., Holzgreve W., Wight E., and Singer G. T4 breast cancer under closer inspection: a case for revision of the TNM classification. Breast 16 6 (2007) 625-636
5. Quirke P., Williams G.T., Ectors N., Ensari A., Piard F., and Nagtegaal I. The future of the TNM staging system in colorectal cancer: time for a debate?. Lancet Oncol 8 7 (2007) 651-657
6. Beachy S.H., and Repasky E.A. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 57 6 (2008) 759-775
7. Keen-Kim D., Nooraie F., and Rao P.N. Cytogenetic biomarkers for human cancer. Front Biosci 13 (2008) 5928-5949
8. Ross J.S., Hatzis C., Symmans W.F., Pusztai L., and Hortobagyi G.N. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13 5 (2008) 477-493
9. Duffy M.J., and Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 54 11 (2008) 1770-1779
10. Dowsett M., and Dunbier A.K. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14 24 (2008) 8019-8026
11. Chang J.H., Vines E., Bertsch H., et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 91 7 (2001) 1231-1237
12. Newman E.A., Guest A.B., Helvie M.A., et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer 107 10 (2006) 2346-2351
13. Watine J., Friedberg B., Nagy E., et al. Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners. Clin Chem 52 1 (2006) 65-72
14. Cordon-Cardo C., Kotsianti A., Verbel D.A., et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 117 7 (2007) 1876-1883
15. Holsinger F.C., and Weber R.S. Swing of the surgical pendulum: a return to surgery for treatment of head and neck cancer in the 21st century?. Int J Radiat Oncol Biol Phys 69 2 Suppl. (2007) S129-S131
16. Pruthi S., Boughey J.C., Brandt K.R., et al. A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. Mayo Clin Proc 82 9 (2007) 1131-1140
17. Gelber R.D., Goldhirsch A., Castiglione M., et al. Time without symptoms and toxicity (TWiST): a quality-of-life-oriented endpoint to evaluate adjuvant therapy. In: Salmon S. (Ed). Adjuvant therapy of cancer (1987), Grune and Stratton, Orlando 455-465
18. Zambo K., Koppan M., Paal A., Schmidt E., Tinneberg H.R., and Bodis J. Sentinel lymph nodes in gynaecological malignancies: frontline between TNM and clinical staging systems?. Eur J Nucl Med Mol Imaging 30 12 (2003) 1684-1688
19. Yau T., Chan P., Ching Chan Y., Wong B.C., Liang R., and Epstein R.J. Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies. Aliment Pharmacol Ther 27 11 (2008) 997-1005
20. Powles T.J., Coombes R.C., Smith I.E., et al. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet i (1980) 580-582
21. Cole B.F., Gelber R.D., Gelber S., Coates A.S., and Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358 9278 (2001) 277-286
22. Cameron D.A., Massie C., Kerr G., and Leonard R.C. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89 10 (2003) 1837-1842
23. Epstein R.J. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 4 11 (2004) 901-909
24. Smithers D.W. Cancer: an attack on cytologism. Lancet i (1962) 493-499
25. Fisher B., Redmond C.K., and Fisher E.R. The contribution of NSABP trials of primary breast cancer therapy to an understanding of tumor biology: an overview of findings. Cancer 46 (1980) 1009-1025
26. Pedrazzini A., Cavalli F., Brunner K., Goldhirsch A., and Mermillod B. Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. Oncology 44 (1987) 51-59
27. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
28. Henderson I.C. Adjuvant systemic therapy for early breast cancer. Cancer 74 1 Suppl. (1994) 401-409